News & Updates
Filter by Specialty:

Dolutegravir plus lamivudine suppresses HIV without HBV reactivation
The two-drug regimen dolutegravir plus lamivudine (DTG/3TC) is as good as 3- or 4-drug antiretroviral therapy (ART) regimens at keeping viral load suppressed while helping avoid hepatitis B virus (HBV) reactivation in people living with HIV-1 who have past exposure to HBV but no immunity, according to a post hoc analysis of five phase 3/3b studies.
Dolutegravir plus lamivudine suppresses HIV without HBV reactivation
07 Aug 2024
KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer
Perioperative pembrolizumab plus chemotherapy confers survival benefit in individuals with locally advanced gastric and gastroesophageal junction (G/GEJ) cancer in the final analysis of the phase III KEYNOTE-585 trial.
KEYNOTE-585 final analysis support perioperative pembrolizumab-chemo for G/GEJ cancer
05 Aug 2024
One-time sigmoidoscopy fends off colorectal cancer risk for up to 2 decades
Once-only screening with flexible sigmoidoscopy appears to provide prolonged protection against colorectal cancer (CRC), reducing both incidence and mortality rates for up to 2 decades, according to the updated results of the UK Flexible Sigmoidoscopy Screening Trial (UKFSST).
One-time sigmoidoscopy fends off colorectal cancer risk for up to 2 decades
02 Aug 2024
Is it safe for coeliac disease patients to take antiobesity drugs?
Patients with coeliac disease (CD) on a gluten-free diet and are treated with antiobesity medications (AOMs) show comparable weight loss outcomes to those without CD, reports a study.